GavinNI, GaynesBN, LohrKN, et al.Perinatal depression: A systematic review of prevalence and incidence. Obstet Gynecol, 2005; 106:1071–1083.
2.
HowardM, DiazZ, BattleC. Implementation of a hospital-based brexanolone program. J Psychiatr Pract, 2022; 28(5):404–408.
3.
ManglaK, HoffmanMC, TrumpffC, et al.Maternal self-harm deaths: An unrecognized and preventable outcome. Am J Obstet Gynecol, 2005; 221:295–303.
4.
LucaDL, MargiottaCA, StaatzC, et al.Financial toll of untreated perinatal mood and anxiety disorders among 2017 births in the United States. Am J Public Health, 2020; 110:888–896.
5.
MajewskaMD, HarrisonNL, SchwartzRD, et al.Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor. Science, 1986; 232(4753):1004–1007.
6.
SchillerCE, Meltzer-BrodyS, RubinowDR. The role of reproductive hormones in postpartum depression. CNS Spectr, 2015; 20:48–59.
7.
Meltzer-BrodyS, ColquhounH, RiesenbergR, et al.Brexanolone injection in post-partum depression: Two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet, 2018; 392:1058–1070.
8.
DeligiannidisKM, Meltzer-BrodyS, MaximosB, et al.Zuranolone for the treatment of postpartum depression. Am J Psychiatry, 2023; 180(9):668–675.
